Shenogen is focused on the discovery and development of first-in-class therapeutics for cancer treatment. After years of efforts, we have developed an impressive product pipeline consisting of small molecule and antibody drugs. Our products are safe and efficient, specifically targeting a novel estrogen receptor ER-alpha 36.

Currently, our lead small molecule SNG-162 is being evaluated in Phase II clinical trial in China. The second generation small molecule SNG-1153 is ready for Investigational New Drug application. Meanwhile, mAbs are developed for therapeutic and diagnostic application.

   Overview